Roche's Genentech subsidiary announced last night that the FDA had handed out an approval for pertuzumab, setting the stage for a new combo attack on HER2-positive cases.
The FDA has a Friday PDUFA deadline to hit after providing pertuzumab a priority review on some significant data on the drug's ability to stall breast cancer when combined with Herceptin (trastuzumab).
T-DM1 lived up to its star billing at ASCO. And in the process investigators highlighted antibody-drug conjugates as the hot new technology in cancer drug development.
After racking up a solid set of late-stage data on the experimental breast cancer drug pertuzumab late last year, Roche ($RHHBY) and Genentech scored priority review status for the program, shaving
Roche and Novartis ($NVS) put out new data yesterday on two treatments that promise to fundamentally reshape the way the majority of breast cancer patients are treated. Roche clearly impressed
After the FDA dropped its breast cancer label on Avastin this month, Swiss pharma giant Roche could regain some steam in early December when it presents full data on its late-stage experimental
Roche has its eyes on another cancer drug approval after the Swiss drug giant met the primary goal of a pivotal trial for a combination therapy against a form of breast cancer. Yet at least one
Genentech ($DNA) has found a new use for a failed drug. At the annual CTRC-AACR San Antonio Breast Cancer Symposium, the drugmaker revealed that pertuzumab and Herceptin in addition to chemotherapy